TEVA:TASETeva Pharmaceutical Industries Limited Analysis

Teva’s share price of $34.07 sits just above its 20‑day SMA of 34.79 and comfortably above the 50‑day SMA of 32.05, confirming a short‑term bullish bias despite a bearish MACD histogram of –0.31. The RSI of 51.4 signals a neutral momentum zone while the 30‑day volatility of 39.9% and a beta of 1.04 indicate the stock moves with the market but experiences pronounced price swings. Fundamentals show a modest 2.3% revenue growth and solid gross margin of 52%, yet the trailing P/E of 25.4× sits below the industry average of 27.6×, implying the stock is priced on the cheaper side of peers; the price‑to‑book of 4.82× is elevated, reflecting a premium valuation on assets. The DCF‑derived fair value of $20.9 per share and an upside/downside potential of 18.2% together with a “Extreme Greed” fear‑greed index suggest upside is still priced in. Recent material news – a $700 million cash acquisition of Emalex Biosciences, a Fitch upgrade to BBB‑ stable outlook, and the appointment of a new EVP of Global R&D – provide concrete catalysts that could lift earnings and cash‑flow generation, reinforcing the bullish technical set‑up. In sum, the stock trades in a bullish technical environment, is modestly undervalued relative to peers, and is backed by strong growth catalysts and an improved credit profile, but heightened volatility and regulatory exposure warrant cautious sizing.